drugset / Trial / NCT04112095

Adherence With Continuous-dose Oral Contraceptive: Evaluation of Self-Selection and Use

NCT04112095

Phase 3 Completed 962 enrolled HRA Pharma
NaSingle-groupOpen-labelOther

Summary

This study is designed to assess whether consumers select and use norgestrel 0.075 mg, a progestin only pill for contraception, in a manner consistent with the OTC package directions in an Over-the-Counter (OTC)-like setting.

Timeline

Start
2019-09-06
Primary completion
2021-08-05
Completion
2021-08-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Norgestrel Unknown 0.075 mg Oral

Indications

No indication recorded.